Quantitation of a novel antiemetic (ADR-851) in plasma and urine by reversed-phase high-performance liquid chromatography with fluorescence detection

• Published in: Journal of chromatography Vol. 566; no. 1; pp. 257 - 265
• Main Authors: Rossi, D.T., Overmyer, S.K., Lewis, R.C., Narang, P.K.
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 03.05.1991; Elsevier
• Subjects: Analysis; Antiemetics - analysis; Antiemetics - blood; Antiemetics - urine; Biological and medical sciences; Chromatography, High Pressure Liquid - methods; Chromatography, High Pressure Liquid - standards; Chromatography, High Pressure Liquid - statistics & numerical data; Drug Stability; General pharmacology; Humans; Medical sciences; Metoclopramide - analogs & derivatives; Metoclopramide - analysis; Metoclopramide - blood; Metoclopramide - urine; Pharmacology. Drug treatments; Quality Control; Biological fluid; Antiemetic; Quantitative analysis
• ISSN: 0378-4347
• DOI: 10.1016/0378-4347(91)80133-W

A sensitive and specific bioanalytical method for quantitation of a novel antiemetic (ADR-851) in plasma and urine has been developed and validated. The drug and internal standard (metoclopramide) are extracted from the plasma matrix by solid-phase extraction on cyanopropyl bonded-phase columns. After extraction, samples are separated by isocratic reversed-phase high-performance liquid chromatography. The parent drug, internal standard and a yet unidentified metabolite are detected by fluorescence. The method requires 1.0 ml of plasma or 0.1 ml of urine and has a lower limit of quantitation of 2 ng/ml with 10.9% relative standard deviation (R.S.D.). Method linearity has been established over a 2–800 ng/ml range when 1.0 ml of plasma is used. The intra- and inter-day imprecisions for the method are typically better than 6% and 11% R.S.D., respectively, in both plasma and urine over the entire dynamic range. The pooled estimate of bias is less than 5% and attests to the excellent accuracy.